Efficacy and safety of dry extract of ivy leaves in therapy of respiratory diseases in children

Abstract

Data of morbidity of respiratory diseases in children at Sankt-Petersburg are given in the article. The authors described significance and current features of respiratory diseases in children, showed a role of mucostasis in poor course and importance of mucoactive therapy in community-acquired and in-hospital respiratory pathologies. Results of post-marketing clinical trial of mucoactive efficacy of Prospan in 180 children of 6 months to 17 years of age with wide-spread respiratory diseases have been presented in the article. High mucolytic and bronchodilating activity and good safety profile of Prospan, which is dry extract of ivy leaves, have been demonstrated. No interaction was noted between Prospan and other medications used in the treatment of respiratory diseases in children. Therapy with dry extract of ivy leaves was safe in children with most prevalent co-existing pathology including early age children.